We appreciated Dr Bergsagel's thoughtful editorial 1 accompanying our paper on the long-term survival of patients in whom metaphase cytogenetic abnormalities were effectively suppressed. 2 We wish to put that work in the context of almost 20 years of clinical trial and translational research in multiple myeloma at the University of Arkansas for Medical Sciences.
When we introduced stem cell-supported high-dose melphalan as a therapeutic strategy for myeloma in the 1980s, we had 
Figure 1
Clinical outcomes of patients treated with total therapies (TT1, TT2 and TT3). Given are Kaplan-Meier plots of patients treated with TT1 (gold), TT2 without thalidomide (green), TT2 with thalidomide (red) and TT3 (blue). The four panels depict overall survival (top left), event-free survival (top right), time to stringently defined complete remission (s-CR; bottom left) and duration of s-CR from its onset (bottom right). The progressive improvement in the four clinical end points is readily appreciated with the transition from TT1 to TT2 to TT3. The plateau in the CR duration curve for TT1 from 10 years onward (bottom right panel, gold) is consistent with cure.
Letters to the Editor employed stringently defined complete remission (CR, immunofixation negativity and absence of aneuploidy or cytoplasmic light chain restriction on flow cytometry) as an early trial objective and surrogate for event-free and overall survival extension. 3 The younger readership needs to be reminded that in those days bone marrow examinations were not routinely performed at diagnosis let alone for re-staging, as all care was strictly palliative in nature. After decades of clinical trial research involving permutations of the melphalan-prednisone (MP) regimen, 4 we demonstrated that high-dose dexamethasone in VAD (vincristine, adriamycin, dexamethasone) was an effective salvage regimen in MP-refractory myeloma. 5 VAD was devoid of hematopoietic stem cell toxicity and thus afforded subsequent collection of autologous bone marrow and soon thereafter peripheral blood stem cells, which were associated with accelerated engraftment and a higher safety margin than 
Figure 2
Clinical outcomes of patients with gene expression profiling (GEP) data on total therapies (TT3 and TT2) according to GEP-defined low-and high-risk designations. Given are Kaplan-Meier plots of patients treated with TT2 without thalidomide (green), TT2 with thalidomide (red) and TT3 (blue). The six panels depict stringently defined complete remission (s-CR) duration from onset of s-CR (top panels), event-free survival (middle panels) and overall survival (bottom panels) according to GEP-defined risk (low risk, left panels; high-risk, right panels). It is apparent, in a TT3-to-TT2 comparison that TT3 significantly improves both CR duration and event-free survival among low-risk patients (upper and middle left panels), while strong trends are noted for improved event-free and overall survival among high-risk patients (middle and bottom right panels).
bone marrow-derived support, especially in the elderly. 6 As a melphalan dose of 200 mg m À2 was the maximum tolerated dose at which significant mucositis occurred, we decided to apply two cycles of melphalan at 200 mg m À2 initially 3-6 months apart in an effort to increase the net antitumor effect, an approach that became known as a 'tandem transplant'. The objective was achieved in that the CR rate was increased from previously 20 to the 40% range, which was associated with prolongation of survival as reported in Total Therapy (TT) 1, the first such trial for newly diagnosed patients employing repeated cycles of stem cell-supported high-dose melphalan. 7 Based on these results, we reasoned that a substantial fraction of patients had to have marked antitumor effect for a substantive proportion of patients to derive long-term benefit. Indeed, recent follow-up analysis of the TT1 trial revealed that among the 231 patients enrolled 54 are alive and 27 are event free, including 14 of the original 87 who entered stringently defined CR (s-CR) and whom we consider cured after 10-16 years of follow-up 8 (update as of 1 January 2008).
In an effort to extend the duration of disease control beyond results obtained with TT1, we evaluated in TT2 the role of thalidomide up-front with more intensified induction prior to tandem transplant and introduced post-transplant consolidation chemotherapy. 9 Results obtained with 668 patients treated showed that the median survival was extended from 6 years with TT1 to more than 8 years with TT2 for both study arms 10 (update as of 1 January 2008: median not reached at 9 years). Importantly, although in this phase III-trial patients randomized to thalidomide had a significantly higher CR rate of 60 versus 40% on the control arm and a significant extension of event-free survival, CR duration was similar between the two study arms, whereas overall survival benefits are only now being recognized, 5 years after treatment initiation; this difference is anticipated to reach significance with further follow-up.
In further studies, we observed that among patients presenting initially with a smoldering clinical course CR rates were substantively lower at B20% compared to the remainder for whom such history was not documented; yet, the median survival durations of the two groups were similar. 11 These data were confirmed when we examined CR rates and survival according to gene expression profiling (GEP)-based signatures defining monoclonal gammopathy of undetermined significance (MGUS)-like versus non-MGUS-like myeloma; superior overall and event-free survival in the former group, which also had a lower CR rate, 12 was noted. We interpreted the findings to indicate that perhaps an MGUS-like state had been reestablished in these patients, reasoning that such a state was highly resistant due to the very low proliferative activity of their plasma cells.
A subsequent publication examined the role of CR in the context of both standard prognostic factors and of a GEP-derived risk index: 13 results showed that CR was critical only for the 15% of patients presenting with high-risk myeloma, 14 arguing that in the case of 'malignant myeloma' profound remission was critical for meaningful survival extension to be achievedF reminiscent of observations in high-versus low-grade lymphoma. These high-risk patients often have complex metaphase cytogenetics indicative of proliferative clones, the elimination of which is central to achieving durable CR.
As we incorporated bortezomib in TT3, 15 the CR frequency was not increased beyond results in the thalidomide arm of TT2, although CR duration and event-free survival were profoundly extended, with a strong trend for survival extension as well (Figure 1) . When results were compared among the patients with available GEP data, the 85% with low-risk disease experienced significant improvements with TT3 in terms of CR duration and event-free survival with no overall survival benefit yet apparent because of short follow-up; the high-risk cohort of patients showed a trend toward improved event-free and overall survival in the TT3-to-TT2 comparison (Figure 2) .
It is now being appreciated that most cases of myeloma comprise, from the outset, a sizable non-or low-secretory myeloma compartment, which can be inferred from the observation of persistent focal lesions noted on magnetic resonance imaging (MRI) examination during CR. 16 Such focal lesions harbor viable tumor cells as shown by 18-fluorodeoxyglucose avidity on PET-CT scanning as well as on cytogenetic and GEP examinations of samples procured from focal lesions under CT guidance. MRI-defined focal lesions, often representing the first site of disease recurrence, can resolve in up to 60% of patients, with a median lag time behind onset of clinical CR of 24 months. Based on the distinctly different GEP features of MRI-defined focal lesions versus simultaneously procured random bone marrow samples, we have raised the issue as to whether such focal lesions may harbor myeloma cells that display stem cell characteristics, an issue currently under investigation.
These data underscore that in the era of high frequencies of marked tumor cytoreduction the issue of serologically and hematologically defined CR needs to be revisited. 17 Indeed, we showed that survival was markedly extended when remissions were sustained 3 years from treatment initiation in comparison to patients never achieving CR status and, importantly, especially those who attained and lost CR status during that time interval. Similarly, our current paper in this issue of the Journal demonstrates that as in the leukemias suppression of an abnormal karyotype on frequent cytogenetic monitoring is key to prolonged survival. 2 Our studies have led us to raise a word of caution about the general usefulness of achieving CR status (appropriately dubbed 'cosmetic CR' by Bergsagel) as a valid surrogate for myeloma survival prediction regardless of its 'benign' or 'malignant' nature, which is best captured by the plasma cell GEP signature. Since follow-up is short, the jury is still out as to whether the unexpectedly high CR rates induced by novel agents translate into sustained disease control as demonstrated here for our TT approach, which combines traditional genotoxic and novel agents toward overcoming the innate resistance of MM cells resulting from their profound genomic instability.
Myelofibrosis is an intramedullary reactive phenomenon, characteristic of the life-threatening myeloproliferative neoplasm of primary myelofibrosis (PMF).
1 Clinically indistinguishable from PMF are the advanced phases of both polycythemia vera (PV) and essential thrombocythemia (ET), in which myelofibrosis is also present (post-PV and post-ET myelofibrosis, respectively (post-PV/ ET MF)).
1 Patients with PMF (or post-ET/PV MF) have a progressive decline marked by progressive cytopenias, extramedullary hematopoiesis (manifesting as splenomegaly and/or hepatomegaly), significant constitutional symptoms, potential for blastic transformation and premature death.
2 Medical therapy for these patients has been disappointing, with clinical benefit being best categorized as palliative with only cosmetic improvements in anemia, splenomegaly or constitutional symptoms seen.
2
Allogeneic stem cell transplantation can be utilized; however, a minority of patients remain appropriate candidates because of non-relapse morbidity and mortality, advanced age at diagnosis, comorbidities or lack of a suitable donor. The urgent need for improved therapeutic options for myelofibrosis patients has fueled scientific investigation into the pathogenetic origins of the disorder in the hope of increasing efficacy through targeted therapy. PMF has been demonstrated to be a stem cell disorder, leading to a clonal myeloproliferation. 3 Origins of the clonal drive are incompletely understood, but are likely, at least in part, secondary to the recently described mutations in the activation of the JAK-STAT pathway by either the JAK2 V617F and/or the MPL W515L/K mutations, which lead to downstream activation of cellular proliferation. 3 In aggregate, these mutations are present in about 50-65% of patients with PMF and post-ET MF, and the majority (V617F only) in post-PV MF. Therapeutic targeting of these latter mutations are currently undergoing initial clinical testing with intriguing results. 4 Prior to the targeting of myeloproliferative neoplasm-associated mutations in cell signaling, therapeutic efforts for myelofibrosis focused on targeting the reactive myelofibrosis in the hope of therapeutic gain.
The significant polyclonal stromal reaction present in PMF (and post-ET/PV MF) leads not only to significant deposition of reticulin fibrosis, but also to collagen fibrosis, osteosclerosis and neoangiogenesis. Increases in several key cytokines have been demonstrated in these patients including transforming growth factor-b1, platelet-derived growth factor and tumor necrosis factor-a. 3 Several clinical trials have been utilized with agents targeting one or more of these aberrant cytokines, in the hope of altering the phenotype of myelofibrosis to that of a less morbid myeloproliferative neoplasm such as PV or ET. Utilizing this strategy, immunomodulatory agents that target tumor necrosis factor-a (with either thalidomide or lenalidomide) 5 have shown clinical benefit. Bortezomib (VELCADE; Millenium Pharmaceuticals Inc. and Johnson & Johnson Pharmaceutical Research and Development, LLC, Cambridge, MA, USA) is a proteosome inhibitor with the ability to inhibit nuclear factor-kB, making it of interest in myelofibrosis. In addition, bortezomib has been shown to (1) inhibit thrombopoietin-induced nuclear factor-kB activation in murine megakaryocytes (2) in murine model of myelofibrosis, therapy with bortezomib decreased transforming growth factor-b1, decreased osteosclerosis, inhibited the cytokine osteoprotegerin and led to increased survival. 6 On the basis of the murine data, theoretical activity by cytokine inhibition, preliminary activity demonstrated in the related myeloid disorder of myelodysplastic syndrome 7 and tolerability shown in the Food and Drug Administration (FDA)-indicated use of bortezomib in
